Abstract
Objective: To investigate the lesion detection rate of <sup>18</sup>F-DCFPyL PET/CT, a prostate-specific membrane antigen (PSMA)-targeted PET agent, in patients with biochemically relapsed prostate cancer after primary local therapy. Methods: This was a prospective institutional review board-approved study of 90 patients with documented biochemical recurrence (median PSA, 2.5 ng/mL) and negative results on conventional imaging. Patients underwent whole-body <sup>18</sup>F-DCFPyL PET/CT. Results were correlated with PSA, PSA kinetics, and original primary tumor grade. Results: 77.8% of patients showed positive PSMA PET results. Detection rates were 47.6%, 50%, 88.9%, and 94% for PSA levels of >0.2 to <0.5, 0.5 to <1.0, 1 to <2.0, and ≥2.0 ng/mL, respectively. In postsurgical patients, PSA kinetics correlated with PET results. Positive predictive value was 93.3% by histopathologic validation. Conclusion: <sup>18</sup>F-DCFPyL PET/CT offers high detection rates in biochemically recurrent prostate cancer patients, even at low PSA levels (<0.5 ng/mL), which could substantially impact clinical management.
Introduction
For many prostate cancer patients, primary treatment—such as radical prostatectomy or radiation—is followed by a period of biochemical recurrence (BCR), characterized by rising prostate-specific antigen (PSA) levels without visible tumors on conventional CT or bone scans. This clinical "ghost hunt" makes it difficult to localize the recurrence and plan effective salvage therapy. While first-generation PSMA tracers have improved detection, they face logistical challenges. This study evaluates <sup>18</sup>F-DCFPyL, a second-generation fluorine-18 labeled tracer that offers superior image resolution and easier distribution from centralized cyclotrons.
Methods
A prospective study was conducted with 90 patients experiencing BCR and negative conventional imaging. The cohort included patients who had undergone radical prostatectomy (n=38), radiation (n=27), or both (n=25). Patients on androgen deprivation therapy were excluded. Whole-body <sup>18</sup>F-DCFPyL PET/CT scans were performed 2 hours post-injection. Findings were correlated with absolute PSA levels and PSA kinetics, specifically doubling time and velocity. Validation was performed via histopathology or clinical follow-up in 40% of positive cases.
Key Results
The overall detection rate was 77.8%, with 287 lesions identified across 70 patients. The majority of these lesions were located in lymph nodes (208), followed by the prostate bed (37) and distant sites (42).
Crucially, the detection rate remained high even at very low PSA levels. For patients with PSA levels between 0.2 and 0.5 ng/mL—the window where salvage therapy is most effective—the tracer identified lesions in 47.6% of cases. Detection rates increased significantly as PSA levels rose, reaching 94% for PSA ≥ 2.0 ng/mL.
In postsurgical patients, PSA doubling time and velocity were strong predictors of a positive scan. However, this correlation was not observed in postradiation patients, suggesting that the remaining treated prostate tissue may confound PSA kinetics as a trigger for imaging.
Discussion and Clinical Impact
The high positive predictive value (93.3% by histology, 96.2% with clinical follow-up) underscores the reliability of <sup>18</sup>F-DCFPyL. Beyond simple detection, the study provided insights into the anatomical spread of recurrent disease. At PSA levels below 1.0 ng/mL, recurrence is typically confined to the pelvis (prostate bed or pelvic lymph nodes). As PSA levels increase, the proportion of extrapelvic disease, including retroperitoneal lymph nodes and bone metastases, rises sharply.
The use of <sup>18</sup>F as a radioisotope offers significant logistical advantages over <sup>68</sup>Ga. With a half-life of 110 minutes, <sup>18</sup>F-DCFPyL can be produced at central manufacturing sites and shipped to regional hospitals, facilitating broader clinical adoption of high-sensitivity PSMA PET imaging.
Conclusion
<sup>18</sup>F-DCFPyL PET/CT is a highly promising tool for localizing recurrent prostate cancer, particularly in patients with low PSA levels where conventional imaging fails. By identifying disease in nearly half of patients with PSA < 0.5 ng/mL, this technology could fundamentally shift the management of biochemical recurrence toward more precise and effective salvage interventions. Future research will focus on whether this early detection translates into improved metastasis-free survival.
Summary updated